Big Pharma claims lower prices means giving up miracle medications. Ignore them
Medicare's drug price negotiations starting January 2026 raise concerns about innovation in pharmaceuticals. However, studies show profitability remains high, and AI may enhance drug development despite lower prices.
Read original articleThe recent implementation of Medicare's drug price negotiations, which will take effect in January 2026, has raised concerns among pharmaceutical companies about potential impacts on future drug innovation. Critics, including major drug manufacturers, argue that lower prices could hinder their ability to invest in research and development for new treatments, including potential cures for diseases like cancer and Alzheimer’s. However, studies suggest that the pharmaceutical industry remains highly profitable, and the anticipated reductions in profit margins are unlikely to significantly deter innovation. Furthermore, the Congressional Budget Office has indicated that the new pricing policy is not expected to have a major effect on future drug development. The article also highlights the potential of artificial intelligence to streamline drug discovery and development processes, which could mitigate concerns about innovation. Overall, the narrative that lower drug prices will necessarily lead to fewer new treatments is challenged by evidence suggesting that the industry can sustain innovation even with reduced prices.
- Medicare's drug price negotiations are set to begin in January 2026.
- Pharmaceutical companies argue that lower prices may stifle innovation, but studies indicate they remain profitable.
- The Congressional Budget Office does not expect significant impacts on future drug development from the new pricing policy.
- AI technology may enhance drug discovery and development, potentially offsetting concerns about innovation.
- The argument that lower prices will lead to fewer new treatments is contested by evidence of the industry's capacity for innovation.
Related
Pharma firms stash profits in Europe's tax havens
Pharma firms hide €580 billion in European tax havens, affecting drug prices and patient access. Companies exploit tax loopholes, impacting healthcare funding. Calls for transparency and accountability in the pharmaceutical industry arise.
Middlemen have outsized influence on drug prices due to market consolidation,FTC
The FTC highlights PBMs' dominance in U.S. drug pricing. Top PBMs control 79% of claims, raising concerns about cost inflation, lack of transparency, and conflicts of interest. Regulation and scrutiny are needed.
The Mafia of Pharma Pricing
The Federal Trade Commission report exposes health care conglomerates, particularly pharmacy benefit managers (PBMs), for inflating drug prices and manipulating the market. PBMs' practices contribute to rising healthcare costs and may lead to potential lawsuits.
Big Tech says AI is booming. Wall Street is starting to see a bubble
Big Tech's investment in AI is projected to reach $60 billion annually by 2026, but analysts doubt profitability, predicting only $20 billion in revenue, amid concerns about a potential investment bubble.
There's No Guarantee AI Will Ever Be Profitable
Silicon Valley tech companies are investing heavily in AI, with costs projected to reach $100 billion by 2027. Analysts question profitability, while proponents see potential for significant economic growth.
If pharma companies lose revenue, they have to cut something. Presumably the intention is to force them to cut profits. I found this analysis of global pharma industry profitability: https://www.ispor.org/docs/default-source/euro2023/poster-is... They found that the average profit margin across the pharma industry was around 20%. So even if pharma companies cut their profits to zero, prices would only drop 20%, right?
And even the idea of cutting profits to zero isn't realistic. Pharma investment is similar to venture capital; investors make risky bets in the hopes that a few of them will pay off big. Why would investors agree to take that risk if they get zero profit in return?
Some people propose things like "the government should fund drug development". OK, that's a fine proposal; it has pros and cons. But that's a very different proposal than "the government should institute price caps on privately-developed drugs". Don't try to justify the latter proposal by conflating it with the former.
Bimzelx (for psoriasis). This costs six figures or more per year, from what I can glean. Watching baseball a lot, I see this advertised multiple times per game, and God only knows what else they spend on marketing.
(I don't have psoriasis or know anyone with it, if that matters)
Looking at UCB's financials (helpfully broken out by drug), they took in $242 million on that drug alone in fiscal 2024. So that's how they can afford all those ads. It's also probably something patients would demand, and maybe even be happy to pay for out of pocket.> they will help the Medicare program cap what individual patients spend out of pocket on their prescriptions in a year at $2,000.
So if you want clear skin, you probably have to pay big bucks. But maybe these immensely profitable drugs subsidize the life-saving ones.
So yes with lower returns investors will look elsewhere. Especially since overall pharma doesn’t really outperform. There’s no alpha across the sector.
So the money has to come from somewhere. If not then yes, innovation will slow down.
* The US premium paid is 150% of R&D costs, therefore cutting it will only cut spending on the costs that aren't R&D
* M&A did not drop in the first year of the program, which covered 10 drugs, therefore the program will have no effect once phased in
* We think AI might develop new drugs for us someday, so it's safe to throw away the existing system today
Not very solid reasons to go after the golden goose!
These wealthy countries are relying on the US to subsidize their medical innovation. The US drug market is the one where the profits are and which determines how much investment is worth it.
> It is a harrowing proposition: that in trying to control drug prices for 67 million Medicare patients now, we might inadvertently prevent the development of future drugs that could save lives. Implied, if not stated outright, is that we’re putting a cure for cancer or Alzheimer’s or some other intractable disease in jeopardy.
Well... given that a lot of the fundamental research in pharmaceuticals happens at universities and/or on taxpayer grants, what exactly is preventing the US government from taking over the later stages of development and the associated risk itself, and only use external providers for manufacturing at scale?
Of course, it's a rhetorical question. The answer is two-fold here - primarily the obvious: large parts of the US (and most Western nations facing similar questions) prefer a "small state", preferably as small as possible. But there's also a second answer... the US' very dark history in government-run medicine. The Tuskeegee syphilis study, the consistent discrimination against PoC and women in medical research, MKULTRA or the US just about permanently burning all of its trust across the world by using "vaccination drives" as a pretext to verify Bin Laden's presence in that compound in Pakistan [1] - antivaxxers, Covid deniers and their ilk didn't sprout up from nothing, they have very fertile soil.
[1] https://www.npr.org/2021/09/06/1034631928/the-cias-hunt-for-...
Related
Pharma firms stash profits in Europe's tax havens
Pharma firms hide €580 billion in European tax havens, affecting drug prices and patient access. Companies exploit tax loopholes, impacting healthcare funding. Calls for transparency and accountability in the pharmaceutical industry arise.
Middlemen have outsized influence on drug prices due to market consolidation,FTC
The FTC highlights PBMs' dominance in U.S. drug pricing. Top PBMs control 79% of claims, raising concerns about cost inflation, lack of transparency, and conflicts of interest. Regulation and scrutiny are needed.
The Mafia of Pharma Pricing
The Federal Trade Commission report exposes health care conglomerates, particularly pharmacy benefit managers (PBMs), for inflating drug prices and manipulating the market. PBMs' practices contribute to rising healthcare costs and may lead to potential lawsuits.
Big Tech says AI is booming. Wall Street is starting to see a bubble
Big Tech's investment in AI is projected to reach $60 billion annually by 2026, but analysts doubt profitability, predicting only $20 billion in revenue, amid concerns about a potential investment bubble.
There's No Guarantee AI Will Ever Be Profitable
Silicon Valley tech companies are investing heavily in AI, with costs projected to reach $100 billion by 2027. Analysts question profitability, while proponents see potential for significant economic growth.